These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 2123602

  • 1. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.
    Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL.
    Am J Cardiol; 1990 Dec 15; 66(20):1412-7. PubMed ID: 2123602
    [Abstract] [Full Text] [Related]

  • 2. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
    Arnout J, Simoons M, de Bono D, Rapold HJ, Collen D, Verstraete M.
    J Am Coll Cardiol; 1992 Sep 15; 20(3):513-9. PubMed ID: 1512327
    [Abstract] [Full Text] [Related]

  • 3. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators.
    N Engl J Med; 1993 Nov 25; 329(22):1615-22. PubMed ID: 8232430
    [Abstract] [Full Text] [Related]

  • 4. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
    Hsia J, Kleiman N, Aguirre F, Chaitman BR, Roberts R, Ross AM.
    J Am Coll Cardiol; 1992 Jul 25; 20(1):31-5. PubMed ID: 1607535
    [Abstract] [Full Text] [Related]

  • 5. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
    Tebbe U, Windeler J, Boesl I, Hoffmann H, Wojcik J, Ashmawy M, Rüdiger Schwarz E, von Loewis P, Rosemeyer P, Hopkins G.
    J Am Coll Cardiol; 1995 Aug 25; 26(2):365-73. PubMed ID: 7608436
    [Abstract] [Full Text] [Related]

  • 6. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL.
    J Am Coll Cardiol; 1994 Apr 25; 23(5):993-1003. PubMed ID: 8144799
    [Abstract] [Full Text] [Related]

  • 7. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD.
    J Am Coll Cardiol; 1994 Dec 25; 24(7):1602-10. PubMed ID: 7963104
    [Abstract] [Full Text] [Related]

  • 8. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
    Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V.
    J Am Coll Cardiol; 1995 Aug 25; 26(2):374-9. PubMed ID: 7608437
    [Abstract] [Full Text] [Related]

  • 9. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
    Thompson PL, Aylward PE, Federman J, Giles RW, Harris PJ, Hodge RL, Nelson GI, Thomson A, Tonkin AM, Walsh WF.
    Circulation; 1991 May 25; 83(5):1534-42. PubMed ID: 1902404
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C, Nordt TK, Peter K, Smalling RW, Runge MS, Kübler W.
    Am J Cardiol; 1996 Dec 19; 78(12A):16-9. PubMed ID: 8990406
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
    Steg PG, Laperche T, Golmard JL, Juliard JM, Benamer H, Himbert D, Aubry P.
    J Am Coll Cardiol; 1998 Mar 15; 31(4):776-9. PubMed ID: 9525545
    [Abstract] [Full Text] [Related]

  • 16. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.
    Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, Nabel EG, Walton JA, Candela RJ, Lee KL.
    J Am Coll Cardiol; 1989 Oct 15; 14(4):877-84. PubMed ID: 2477426
    [Abstract] [Full Text] [Related]

  • 17. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A.
    Circulation; 1995 Jun 01; 91(11):2725-32. PubMed ID: 7758177
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction.
    van der Wieken LR, Simoons ML, Laarman GJ, Van den Brand M, Nijssen KM, Dellborg M, Hermens W, Vrolik W.
    Int J Cardiol; 1995 Nov 24; 52(2):125-34. PubMed ID: 8749872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.